866-997-4948(US-Canada Toll Free)

Small-Cell Lung Cancer - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Jun 2015

Category :

Cancer

No. of Pages : 504 Pages

Small-Cell Lung Cancer - Pipeline Review, H1 2015

Summary

Global Markets Directs, Small-Cell Lung Cancer - Pipeline Review, H1 2015, provides an overview of the Small-Cell Lung Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Small-Cell Lung Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Small-Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Small-Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Small-Cell Lung Cancer Overview 11
Therapeutics Development 12
Pipeline Products for Small-Cell Lung Cancer - Overview 12
Pipeline Products for Small-Cell Lung Cancer - Comparative Analysis 13
Small-Cell Lung Cancer - Therapeutics under Development by Companies 14
Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes 20
Small-Cell Lung Cancer - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Small-Cell Lung Cancer - Products under Development by Companies 25
Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes 32
Small-Cell Lung Cancer - Companies Involved in Therapeutics Development 33
A. Menarini Industrie Farmaceutiche Riunite Srl 33
AbbVie Inc. 34
Alchemia Limited 35
Amgen Inc. 36
Aposense Ltd. 37
Array BioPharma Inc. 38
Astellas Pharma Inc. 39
AstraZeneca Plc 40
AVEO Pharmaceuticals, Inc. 41
Bayer AG 42
BIND Therapeutics, Inc. 43
Blend Therapeutics, Inc. 44
Boehringer Ingelheim GmbH 45
Bristol-Myers Squibb Company 46
Cantex Pharmaceuticals, Inc. 47
Celator Pharmaceuticals, Inc. 48
CellAct Pharma GmbH 49
Cerulean Pharma, Inc. 50
Cornerstone Pharmaceuticals, Inc. 51
Critical Outcome Technologies Inc. 52
CytRx Corporation 53
Eisai Co., Ltd. 54
Eli Lilly and Company 55
Exelixis, Inc. 56
F. Hoffmann-La Roche Ltd. 57
GlaxoSmithKline Plc 58
Hutchison MediPharma Limited 59
ImmunoCellular Therapeutics, Ltd. 60
Immunomedics, Inc. 61
Inbiopro Solutions Pvt. Ltd. 62
Johnson & Johnson 63
Karyopharm Therapeutics, Inc. 64
Kolltan Pharmaceuticals, Inc. 65
Kyowa Hakko Kirin Co., Ltd. 66
Lindis Biotech GmbH 67
MabVax Therapeutics Holdings, Inc. 68
MedImmune, LLC 69
MEI Pharma, Inc. 70
Merck & Co., Inc. 71
Mersana Therapeutics, Inc. 72
Millennium Pharmaceuticals, Inc. 73
Mirna Therapeutics, Inc. 74
MolMed S.p.A. 75
Mologen AG 76
Nektar Therapeutics 77
Neotropix, Inc. 78
Nippon Kayaku Co., Ltd. 79
Novartis AG 80
Omnitura Therapeutics Inc. 81
OncoMed Pharmaceuticals, Inc. 82
Ono Pharmaceutical Co., Ltd. 83
Onxeo SA 84
Onyx Pharmaceuticals, Inc. 85
Oxford BioTherapeutics Ltd 86
Pfizer Inc. 87
Polaris Pharmaceuticals, Inc. 88
Rexahn Pharmaceuticals, Inc. 89
Spectrum Pharmaceuticals, Inc. 90
Sumitomo Dainippon Pharma Co., Ltd. 91
Synta Pharmaceuticals Corp. 92
Tesaro, Inc. 93
Vertex Pharmaceuticals Incorporated 94
Zensun (Shanghai) Sci & Tech Co., Ltd. 95
ZIOPHARM Oncology, Inc. 96
Small-Cell Lung Cancer - Therapeutics Assessment 97
Assessment by Monotherapy Products 97
Assessment by Combination Products 98
Assessment by Target 99
Assessment by Mechanism of Action 107
Assessment by Route of Administration 113
Assessment by Molecule Type 115
Drug Profiles 117
(irinotecan hydrochloride + cisplatin) - Drug Profile 117
5B1 - Drug Profile 118
ABT-737 - Drug Profile 119
Adva-27a - Drug Profile 121
aldoxorubicin hydrochloride - Drug Profile 123
alisertib - Drug Profile 126
amrubicin hydrochloride - Drug Profile 130
ATT-11T - Drug Profile 132
AV-203 - Drug Profile 133
AZD-2811 - Drug Profile 134
AZD-3965 - Drug Profile 135
belinostat - Drug Profile 137
binimetinib - Drug Profile 140
BIW-8962 - Drug Profile 145
BMS-986012 - Drug Profile 146
BMS-986158 - Drug Profile 148
BTP-277 - Drug Profile 149
cabozantinib s-malate - Drug Profile 150
CAP-7.1 - Drug Profile 153
carboplatin - Drug Profile 155
carfilzomib - Drug Profile 156
Cell Therapy 1 for Oncology - Drug Profile 160
COTI-2 - Drug Profile 161
COTI-219 - Drug Profile 164
COTI-4 - Drug Profile 165
COTI-58 - Drug Profile 166
CPI-613 - Drug Profile 167
CRLX-101 - Drug Profile 169
CX-01 - Drug Profile 171
Cyt-PLAT - Drug Profile 173
durvalumab + tremelimumab - Drug Profile 174
erismodegib - Drug Profile 176
etirinotecan pegol - Drug Profile 179
etoposide phosphate next generation - Drug Profile 182
ganetespib - Drug Profile 183
ganitumab - Drug Profile 187
GSK-2879552 - Drug Profile 190
HMPL-453 - Drug Profile 191
IBPM-002BZ - Drug Profile 192
ICT-109 - Drug Profile 193
indisulam - Drug Profile 195
ipilimumab - Drug Profile 196
irinotecan hydrochloride - Drug Profile 200
JNJ-42756493 - Drug Profile 202
KIT-SG3227 - Drug Profile 204
LOP-628 - Drug Profile 206
LY-2510924 - Drug Profile 207
ME-344 - Drug Profile 208
MGN-1703 - Drug Profile 210
MK-2206 + selumetinib sulfate - Drug Profile 213
Monoclonal Antibodies to Inhibit Vasopressin V2 Receptor for Small-Cell Lung Cancer - Drug Profile 215
MRX-34 - Drug Profile 216
MX-225 - Drug Profile 218
NGR-hTNF - Drug Profile 219
nintedanib - Drug Profile 223
niraparib - Drug Profile 228
nivolumab - Drug Profile 230
NK-012 - Drug Profile 236
NTX-010 - Drug Profile 238
olaparib - Drug Profile 240
OMN-54 - Drug Profile 244
OSI-930 - Drug Profile 246
OX-004 - Drug Profile 247
palifosfamide - Drug Profile 248
pegargiminase - Drug Profile 250
pembrolizumab - Drug Profile 253
PF-4989216 - Drug Profile 260
Recombinant Peptide to Target EGFR for Oncology - Drug Profile 261
RG-6016 - Drug Profile 262
rilotumumab - Drug Profile 264
roniciclib - Drug Profile 266
RX-3117 - Drug Profile 268
sabarubicin - Drug Profile 269
sacituzumab govitecan - Drug Profile 271
SC-16LD6.5 - Drug Profile 272
selinexor - Drug Profile 273
Small Molecules for Small Cell Lung Cancer - Drug Profile 278
Small Molecules to Inhibit EZH2-EED for Cancer - Drug Profile 279
solitomab - Drug Profile 280
STA-128666 - Drug Profile 281
STA-129183 - Drug Profile 283
taladegib - Drug Profile 284
tarextumab - Drug Profile 285
temozolomide - Drug Profile 287
TF-2 - Drug Profile 289
topotecan hydrochloride liposomal - Drug Profile 291
Tozaride - Drug Profile 292
TRBS-07 - Drug Profile 294
Vaccine for Small Cell Lung Cancer - Drug Profile 295
vandetanib - Drug Profile 297
veliparib - Drug Profile 303
vinorelbine tartrate liposomal - Drug Profile 306
vorinostat - Drug Profile 308
VX-970 - Drug Profile 312
X-396 - Drug Profile 313
XMT-1001 - Drug Profile 314
ZS-05 - Drug Profile 316
Small-Cell Lung Cancer - Recent Pipeline Updates 317
Small-Cell Lung Cancer - Dormant Projects 481
Small-Cell Lung Cancer - Discontinued Products 486
Small-Cell Lung Cancer - Product Development Milestones 488
Featured News & Press Releases 488
Appendix 496
Methodology 496
Coverage 496
Secondary Research 496
Primary Research 496
Expert Panel Validation 496
Contact Us 496
Disclaimer 497

List of Tables
Number of Products under Development for Small-Cell Lung Cancer, H1 2015 19
Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H1 2015 20
Number of Products under Development by Companies, H1 2015 22
Number of Products under Development by Companies, H1 2015 (Contd..1) 23
Number of Products under Development by Companies, H1 2015 (Contd..2) 24
Number of Products under Development by Companies, H1 2015 (Contd..3) 25
Number of Products under Development by Companies, H1 2015 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H1 2015 27
Comparative Analysis by Late Stage Development, H1 2015 28
Comparative Analysis by Clinical Stage Development, H1 2015 29
Comparative Analysis by Early Stage Development, H1 2015 30
Comparative Analysis by Unknown Stage Development, H1 2015 31
Products under Development by Companies, H1 2015 32
Products under Development by Companies, H1 2015 (Contd..1) 33
Products under Development by Companies, H1 2015 (Contd..2) 34
Products under Development by Companies, H1 2015 (Contd..3) 35
Products under Development by Companies, H1 2015 (Contd..4) 36
Products under Development by Companies, H1 2015 (Contd..5) 37
Products under Development by Companies, H1 2015 (Contd..6) 38
Products under Investigation by Universities/Institutes, H1 2015 39
Small-Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 40
Small-Cell Lung Cancer - Pipeline by AbbVie Inc., H1 2015 41
Small-Cell Lung Cancer - Pipeline by Alchemia Limited, H1 2015 42
Small-Cell Lung Cancer - Pipeline by Amgen Inc., H1 2015 43
Small-Cell Lung Cancer - Pipeline by Aposense Ltd., H1 2015 44
Small-Cell Lung Cancer - Pipeline by Array BioPharma Inc., H1 2015 45
Small-Cell Lung Cancer - Pipeline by Astellas Pharma Inc., H1 2015 46
Small-Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2015 47
Small-Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 48
Small-Cell Lung Cancer - Pipeline by Bayer AG, H1 2015 49
Small-Cell Lung Cancer - Pipeline by BIND Therapeutics, Inc., H1 2015 50
Small-Cell Lung Cancer - Pipeline by Blend Therapeutics, Inc., H1 2015 51
Small-Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 52
Small-Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2015 53
Small-Cell Lung Cancer - Pipeline by Cantex Pharmaceuticals, Inc., H1 2015 54
Small-Cell Lung Cancer - Pipeline by Celator Pharmaceuticals, Inc., H1 2015 55
Small-Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H1 2015 56
Small-Cell Lung Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015 57
Small-Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 58
Small-Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2015 59
Small-Cell Lung Cancer - Pipeline by CytRx Corporation, H1 2015 60
Small-Cell Lung Cancer - Pipeline by Eisai Co., Ltd., H1 2015 61
Small-Cell Lung Cancer - Pipeline by Eli Lilly and Company, H1 2015 62
Small-Cell Lung Cancer - Pipeline by Exelixis, Inc., H1 2015 63
Small-Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 64
Small-Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H1 2015 65
Small-Cell Lung Cancer - Pipeline by Hutchison MediPharma Limited, H1 2015 66
Small-Cell Lung Cancer - Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2015 67
Small-Cell Lung Cancer - Pipeline by Immunomedics, Inc., H1 2015 68
Small-Cell Lung Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 69
Small-Cell Lung Cancer - Pipeline by Johnson & Johnson, H1 2015 70
Small-Cell Lung Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 71
Small-Cell Lung Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2015 72
Small-Cell Lung Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 73
Small-Cell Lung Cancer - Pipeline by Lindis Biotech GmbH, H1 2015 74
Small-Cell Lung Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015 75
Small-Cell Lung Cancer - Pipeline by MedImmune, LLC, H1 2015 76
Small-Cell Lung Cancer - Pipeline by MEI Pharma, Inc., H1 2015 77
Small-Cell Lung Cancer - Pipeline by Merck & Co., Inc., H1 2015 78
Small-Cell Lung Cancer - Pipeline by Mersana Therapeutics, Inc., H1 2015 79
Small-Cell Lung Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 80
Small-Cell Lung Cancer - Pipeline by Mirna Therapeutics, Inc., H1 2015 81
Small-Cell Lung Cancer - Pipeline by MolMed S.p.A., H1 2015 82
Small-Cell Lung Cancer - Pipeline by Mologen AG, H1 2015 83
Small-Cell Lung Cancer - Pipeline by Nektar Therapeutics, H1 2015 84
Small-Cell Lung Cancer - Pipeline by Neotropix, Inc., H1 2015 85
Small-Cell Lung Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2015 86
Small-Cell Lung Cancer - Pipeline by Novartis AG, H1 2015 87
Small-Cell Lung Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2015 88
Small-Cell Lung Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 89
Small-Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 90
Small-Cell Lung Cancer - Pipeline by Onxeo SA, H1 2015 91
Small-Cell Lung Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 92
Small-Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H1 2015 93
Small-Cell Lung Cancer - Pipeline by Pfizer Inc., H1 2015 94
Small-Cell Lung Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 95
Small-Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 96
Small-Cell Lung Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 97
Small-Cell Lung Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 98
Small-Cell Lung Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 99
Small-Cell Lung Cancer - Pipeline by Tesaro, Inc., H1 2015 100
Small-Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 101
Small-Cell Lung Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2015 102
Small-Cell Lung Cancer - Pipeline by ZIOPHARM Oncology, Inc., H1 2015 103
Assessment by Monotherapy Products, H1 2015 104
Assessment by Combination Products, H1 2015 105
Number of Products by Stage and Target, H1 2015 107
Number of Products by Stage and Mechanism of Action, H1 2015 115
Number of Products by Stage and Route of Administration, H1 2015 121
Number of Products by Stage and Molecule Type, H1 2015 123
Small-Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H1 2015 324
Small-Cell Lung Cancer - Dormant Projects, H1 2015 488
Small-Cell Lung Cancer - Dormant Projects (Contd..1), H1 2015 489
Small-Cell Lung Cancer - Dormant Projects (Contd..2), H1 2015 490
Small-Cell Lung Cancer - Dormant Projects (Contd..3), H1 2015 491
Small-Cell Lung Cancer - Dormant Projects (Contd..4), H1 2015 492
Small-Cell Lung Cancer - Discontinued Products, H1 2015 493
Small-Cell Lung Cancer - Discontinued Products (Contd..1), H1 2015 494

List of Figures
Number of Products under Development for Small-Cell Lung Cancer, H1 2015 19
Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H1 2015 20
Number of Products under Development by Companies, H1 2015 21
Comparative Analysis by Late Stage Development, H1 2015 28
Comparative Analysis by Clinical Stage Development, H1 2015 29
Comparative Analysis by Early Stage Products, H1 2015 30
Assessment by Monotherapy Products, H1 2015 104
Assessment by Combination Products, H1 2015 105
Number of Products by Top 10 Targets, H1 2015 106
Number of Products by Stage and Top 10 Targets, H1 2015 106
Number of Products by Top 10 Mechanism of Actions, H1 2015 114
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 114
Number of Products by Top 10 Routes of Administration, H1 2015 120
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 120
Number of Products by Top 10 Molecule Types, H1 2015 122
Number of Products by Stage and Top 10 Molecule Types, H1 2015 122

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *